Two pieces of research crossed my desk in the past couple of weeks regarding advanced PCa scanning. The first is a short, easy to read review of two studies by our friend Dr. Fabio Almeida in Phoenix, Az that summarizes what we often discuss in our virtual groups ….. that the Gallium 68 PSMA scan is roughly speaking twice as effective as the Axumin scan; and that both are much more effective at higher PSA’s. The likelihood of detecting cancer at a recurrent PSA of 1.00 is about double the rate at less than 0.5. Many thanks to the Silicon Valley UsTOO Advanced PCa group for circulating this and to Peter Kafka for forwarding to me.
The second piece of information to highlight comes from a recent PCI post regarding the even better scanning technique 18F-DCFPyl currently being trialed by NIH in Bethesda, MD and elsewhere. Preliminary results of the CONDOR trial suggest that 48 of 55 men in total changed their disease management plans as a result of the scanning result. This is a small sample, and there are an additional 145 men admitted to this trial whose results have not yet been included.